ACOG
Alpha Cognition IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$135.00M
P/E Ratio
—
EPS
$-1.18
Beta
2.52
52W High
$11.54
52W Low
$4.50
50-Day MA
$6.04
200-Day MA
$6.87
Dividend Yield
—
Profit Margin
-202.20%
Forward P/E
26.88
PEG Ratio
—
About Alpha Cognition Inc
Alpha Cognition Inc. is an innovative biopharmaceutical firm focused on developing advanced therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its flagship product, ACOG-100, aims to improve cognitive function and fulfill critical unmet medical needs among the aging population. Leveraging a proprietary neuroscience platform and a comprehensive R&D strategy, the company is poised to make significant strides in patient care. As Alpha Cognition progresses with its clinical pipeline and explores new therapeutic options, it presents an appealing investment opportunity for institutional investors seeking to engage with the transformative healthcare sector.
Fundamentals
| Revenue (TTM) | $10.22M |
| Gross Profit (TTM) | $8.30M |
| EBITDA | $-22.60M |
| Operating Margin | -283.70% |
| Return on Equity | -40.70% |
| Return on Assets | -21.70% |
| Revenue/Share (TTM) | $0.58 |
| Book Value | $2.87 |
| Price-to-Book | 2.16 |
| Price-to-Sales (TTM) | 13.21 |
| EV/Revenue | 8.55 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $21.77M |
| Float | $11.03M |
| % Insiders | 9.79% |
| % Institutions | 52.65% |
Historical Volatility
HV 10-Day
51.62%
HV 20-Day
77.31%
HV 30-Day
69.47%
HV 60-Day
73.28%
HV Rank
35.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($16.00 target)
1
BuyData last updated: 4/29/2026